Table 1.
Median percentage change from baseline to week 24 in spleen volume and total symptom scores by final titrated ruxolitinib dose in COMFORT-I
| Final titrated doseb
|
||||||
|---|---|---|---|---|---|---|
| Median % changea | Placebo n=106 | ≤5 mg BID n=21 | 10 mg BID n=30 | 15 mg BID n=24 | 20 mg BID n=40 | 25 mg BID n=21 |
| Spleen volume | 9.2 | −10.4 | −30.8 | −35.9 | −38.4 | −40.9 |
| TSS | 14.6 | −17.5 | −71.1 | −59.6 | −67.7 | −66.2 |
| Abdominal TSS | 10.1 | −11.7 | −80.6 | −76.5 | −65.2 | −71.1 |
| Cytokine TSS | 20.4 | −6.8 | −77.4 | −73.7 | −62.9 | −43.7 |
Notes: Abdominal TSS includes symptom scores for abdominal pain, pain under left ribs, and early satiety; cytokine TSS includes symptom scores for night sweats, itching, and bone/muscle pain; TSS is the sum of these six individual symptom scores.
a
A negative value indicates improvement;
b
final titrated dose was defined as the average daily dose from week 21 to week 24.
Abbreviations: COMFORT, COntrolled Myelofibrosis study with ORal JAK (Janus kinase) inhibitor Treatment; BID, bis in die (twice daily); TSS, total symptom score.